Literature DB >> 9768656

Human growth hormone treatment of short-stature children born small for gestational age: effect on muscle and adipose tissue mass during a 3-year treatment period and after 1 year's withdrawal.

J Leger1, C Garel, A Fjellestad-Paulsen, M Hassan, P Czernichow.   

Abstract

In addition to its growth promoting effect, GH has profound metabolic effects that have not always been evaluated in longitudinal studies. We have recently shown that the effect of GH on body composition can be evaluated by magnetic resonance imaging measurement of adipose and muscle tissue cross-sectional (cs) areas in the thigh. The aim of this study was to evaluate the long-term effects of human GH (hGH) (0.2 IU/kg day) on muscle and adipose tissue mass during a 3-yr treatment period and after 1 year's withdrawal in short SGA (small for gestational age) children. Measurement of muscle and fat tissue mass by magnetic resonance imaging of the thighs was used to study the metabolic effect of hGH in 14 prepubertal short children born SGA. Results were compared with those of a control group of 7 normal children followed longitudinally. An increase of muscle tissue cs area was observed during the 3 yr of hGH treatment, an increase which was significantly different during the first 2 yr of treatment from that seen in controls (+31.2+/-2.6% and +18.1+/-1.8% during the 1st and 2nd year, respectively, vs. +9.1+/-2.6% change during 1 yr in controls). After a significant decrease in adipose tissue cs area during the first year of therapy (-16.4+/-3.4% vs. baseline values), an increase in adipose tissue cs area occurred during the second and third years. At the end of the third year, the muscle tissue cs area change was significantly greater in SGA-treated children, as compared with controls (+71.6+/-4.6% vs. 22.1+/-4.6%; P < 0.001), whereas the adipose tissue cs area change was similar in the two groups (+12.6+/-9.5% vs. +19.9+/-4.2%). After hGH withdrawal, the effects were opposite after 3 months, as compared with those observed after the first 3 months of hGH administration, whereas no additional significant change was seen after 1 yr off treatment, indicating the maintenance of muscle and adipose tissue mass. In conclusion, hGH administered to SGA children is effective in improving growth velocity and has long-term effects on muscle and adipose tissue mass. These effects may lead to speculation about the sensitivity of these tissues to GH. The physiological consequences of such effects must be evaluated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9768656     DOI: 10.1210/jcem.83.10.5165

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Treatment with growth hormone in short children born with intrauterine growth retardation.

Authors:  P Czernichow
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

Review 2.  Claims for the anabolic effects of growth hormone: a case of the emperor's new clothes?

Authors:  M J Rennie
Journal:  Br J Sports Med       Date:  2003-04       Impact factor: 13.800

3.  Small for gestation and growth hormone therapy.

Authors:  Archana Dayal Arya
Journal:  Indian J Pediatr       Date:  2006-01       Impact factor: 1.967

Review 4.  Efficacy and safety of growth hormone treatment for children born small for gestational age.

Authors:  Il Tae Hwang
Journal:  Korean J Pediatr       Date:  2014-09-30

Review 5.  Should recombinant human growth hormone therapy be used in short small for gestational age children?

Authors:  L B Johnston; M O Savage
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

6.  Recombinant human growth hormone for children born small for gestational age: meta-analysis confirms the consistent dose-effect relationship on catch-up growth.

Authors:  R Crabbé; M von Holtey; P Engrand; P Chatelain
Journal:  J Endocrinol Invest       Date:  2008-04       Impact factor: 4.256

7.  Latin American consensus: children born small for gestational age.

Authors:  Margaret C S Boguszewski; Veronica Mericq; Ignacio Bergada; Durval Damiani; Alicia Belgorosky; Peter Gunczler; Teresa Ortiz; Mauricio Llano; Horacio M Domené; Raúl Calzada-León; Armando Blanco; Margarita Barrientos; Patricio Procel; Roberto Lanes; Orlando Jaramillo
Journal:  BMC Pediatr       Date:  2011-07-19       Impact factor: 2.125

8.  Can growth hormone treatment improve growth in children with severe growth failure due to anorexia nervosa? A preliminary pilot study.

Authors:  Juliane Léger; Anne Fjellestad-Paulsen; Anne Bargiacchi; Catherine Doyen; Emmanuel Ecosse; Jean-Claude Carel; Marie-France Le Heuzey
Journal:  Endocr Connect       Date:  2017-10-16       Impact factor: 3.335

9.  Developmental programming of somatic growth, behavior and endocannabinoid metabolism by variation of early postnatal nutrition in a cross-fostering mouse model.

Authors:  Felix Schreiner; Merle Ackermann; Michael Michalik; Eva Hucklenbruch-Rother; Andras Bilkei-Gorzo; Ildiko Racz; Laura Bindila; Beat Lutz; Jörg Dötsch; Andreas Zimmer; Joachim Woelfle
Journal:  PLoS One       Date:  2017-08-31       Impact factor: 3.240

Review 10.  Human Growth and Growth Hormone: From Antiquity to the Recominant Age to the Future.

Authors:  Evan Graber; Edward O Reiter; Alan D Rogol
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-05       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.